This alert card contains important safety information that you need to be aware of before, during and after stopping treatment with Tysabri (natalizumab). Hard copies can be requested by contacting Biogen at [email protected] or by telephone on 0800 008 7401.

This guidance document has been developed for those physicians initiating and supervising TYSABRI in accordance with the conditions of the Marketing Authorisation of the drug.

This form should be read carefully before continuing TYSABRI treatment for more than 2 years.

This form should be read carefully before discontinuing treatment with TYSABRI.

This form should be read carefully before starting treatment with TYSABRI.

Outside a Clinical Setting (OCS) Administration Checklist. Pre-dose checklist for Healthcare Professionals to reduce the risk of progressive multifocal leucoencephalopathy (PML) associated with subcutaneous TYSABRI (natalizumab).

Healthcare Professional Guide to the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI (natalizumab). This supplement is intended for use by Healthcare Professionals (HCPs) administering TYSABRI subcutaneous (SC) outside a clinical setting (OCS).